Files
Document type
ArticleVersion
Published versionPublication date
Publication license
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/177753
The DNA methylation landscape of hematological malignancies: an update
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
The rapid advances in high-throughput sequencing technologies have made it more evident that epigenetic modifications orchestrate a plethora of complex biological processes. During the last decade, we have gained significant knowledge about a wide range of epigenetic changes that crucially contribute to some of the most aggressive forms of leukemia, lymphoma and myelodysplastic syndromes. DNA methylation is a key epigenetic player in the abnormal initiation, development and progression of these malignancies, often acting in synergy with other epigenetic alterations. It also contributes to the acquisition of drug resistance. In this review, we summarize the role of DNA methylation in hematological malignancies described in the current literature. We discuss in detail the dual role of DNA methylation in normal and aberrant hematopoiesis, as well as the involvement of this type of epigenetic change in other aspects of the disease. Finally, we present a comprehensive overview of the main clinical implications, including a discussion of the therapeutic strategies that regulate or reverse aberrant DNA methylation patterns in hematological malignancies, including their combination with (chemo-) immunotherapy.
Subject
Subject (English)
Citation
Citation
BLECUA, Pedro, MARTINEZ-VERBO, Laura and ESTELLER, Manel. The DNA methylation landscape of hematological malignancies: an update. Molecular Oncology. 2020. Vol. 14, num. 8, pags. 1616-1639. ISSN 1574-7891. [consulted: 17 of June of 2026]. Available at: https://hdl.handle.net/2445/177753